Continuous glucose monitoring (CGM) is a latest technological advancement in the field of diabetes management. CGM system is a type of device that monitors glucose by a biosensor, which is inserted through the transcutaneous or subcutaneous route. This embedded sensor measures glucose levels in interstitial fluid or blood, and transmits the information using a transmitter to a receiver/monitor to display the results. The use of CGM systems is crucial to avoid diabetic complications, as this technology can be used to periodically monitor the glucose levels. Therefore, glucose monitoring device manufacturing companies focus on the development of novel and technologically advanced CGMS. It offers a wide range of applications for all age cohorts, healthcare settings (diagnostic centers/clinics, hospital ICUs, and home healthcare), and geographies. Thus, CGMS market poses lucrative opportunities for both CGMS manufacturers and insulin pump manufacturers.
The European CGMS market generated $58 million in 2015, and is projected to reach $792 million by 2022, expanding at a CAGR of 44.9% during the forecast period. High-tech CGMS devices, such as wearable & smartphone-connected CGMS, non-invasive CGMS, smartphone-connected CGMS, and “smart” diabetes management solution (also called artificial/bionic pancreas), are expected to result in higher adoption of CGMS among endocrinologists and patients.
The market is categorized based on component, demographics, end user, and country. The component segment includes durable components such as transmitters & receivers and integrated insulin pumps; and disposable components such as sensors. Sensors occupy a dominant share in the European CGMS market owing to short life span of these devices, recurring sales of CGMS, and bulk purchases. Therefore, they are deployed in diagnostic centers/clinics. Moreover, the adoption of CGMS in hospital ICUs and in-home healthcare settings has increased in recent years. End users of CGMS devices are diabetic patients, categorized into child population (≤14 years) and adult population (>14 years).
The report includes comprehensive analysis and segmentation of different countries in Europe, including UK, France, Germany, Spain, Italy, the Netherlands, Norway, Sweden, Denmark, Finland, and rest of Europe.
Major strategies adopted by market players are collaborations, product launches, and product approvals. Agreement/partnership strategy by companies enables greater focus on innovation, distribution, and commercialization of devices. For instance, in 2016, Senseonics signed an agreement with Roche to commercialize Senseonics’ Eversense continuous glucose monitoring system. Under this agreement, Roche can sell its CGM systems in Germany, Italy, and the Netherlands
KEY MARKET BENEFITS
In-depth and country-level analysis provides the current trends and future estimations in the European CGMS market from 2014 to 2022, which would enable stakeholders to capitalize on the prevailing market opportunities.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
In-depth analysis of current research and clinical developments within the European CGMS market is provided along with the key dynamic factors.
The key players in the European CGMS market are profiled, along with their development strategies, to understand the competitive outlook.
KEY MARKET SEGMENTS:
Transmitters & Receivers
Integrated Insulin Pumps
Child Population (≤14 years)
Adult Population (>14 years)
By End User
Rest of Europe
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION
3.2. NEED FOR GLUCOSE MONITORING SYSTEMS
3.2.1. Diabetesa pandemic
188.8.131.52. Type 1 diabetes
184.108.40.206. Type-2 diabetes
220.127.116.11. Prediabetes and gestational diabetes mellitus (GDM)
18.104.22.168. Gestational diabetes mellitus (GDM)
22.214.171.124. Secondary diabetes
126.96.36.199. Global healthcare expenditure on diabetes
3.3. TECHNOLOGICAL ADVANCEMENTS IN CGMS
3.3.1. Smartphone-connected CGMS
188.8.131.52 Wearable and smartphone-connected CGMS
184.108.40.206. 'Smart diabetes management solutionbionic/artificial pancreas
220.127.116.11. Non-invasive CGMS
18.104.22.168. Invasive CGMS
3.3.2. CGMS: PRIME END USER SEGMENTS
22.214.171.124. CGMS: role in intensive care units (ICUs)
126.96.36.199.1. Stress hyperglycemia: common occurrence in ICUs
188.8.131.52. Non-standardization and erroneous glycemic control across ICUs
184.108.40.206. Benefits and driving factors of CGMS in ICUs
220.127.116.11.1. Use of CGMS for tight glycemic control in ICUs
18.104.22.168.2. Cost benefits due to use of CGMS
22.214.171.124.3. Lower effectiveness of POC glucometers than CGMS in ICUs
126.96.36.199.4. CGMS: most preferred by ICU staff
3.4. KEY FINDINGS
3.4.1. Top investment pockets
188.8.131.52. CGMS market, by components
3.4.2. Top winning strategies
3.5. PATENT ANALYSIS
3.6. MARKET SHARE ANALYSIS, 2015
3.7. GOVERNMENT REGULATIONS
3.7.1. ISO regulations (ISO 13485:2003)
184.108.40.206. Objective and Scope of ISO 13485:2003
3.8. EUROPE REIMBURSEMENT SCENARIO
3.9. MARKET DYNAMICS
220.127.116.11. Benefits of CGMS over POC glucometers
18.104.22.168. Rise in incidence of diabetes cases
22.214.171.124. Technological advancements
126.96.36.199. Adverse effects and accuracy
188.8.131.52. Reimbursement and stringent regulatory issues
184.108.40.206. High adoption rate of CGMS in home healthcare and ICUs
220.127.116.11. Increase in product awareness
18.104.22.168. High undiagnosed patient population
CHAPTER 4 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS
4.1.1. Market size and forecast
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.3. TRANSMITTERS & RECEIVERS
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.4. INTEGRATED INSULIN PUMPS
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKETBY DEMOGRAPHICS
5.1.1. Market size and forecast
5.2. ADULT POPULATION (>14 YEARS)
5.2.1. Market size and forecast
5.3. CHILDREN POPULATION (14 YEARS)
5.3.1. Market size and forecast
CHAPTER 6 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER
6.1.1. Market size and forecast
6.2. DIAGNOSTIC CENTERS/CLINICS
6.2.1. Market size and forecast
6.3.1. Market size and forecast
6.4. HOME HEALTHCARE
6.4.1. Market size and forecast
CHAPTER 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY
7.1.1. Key market trends
7.1.2. Key growth factors and opportunities
7.1.3. Market size and forecast
22.214.171.124. Market size and forecast
126.96.36.199. Market size and forecast
188.8.131.52. Market size and forecast
184.108.40.206. Market size and forecast
220.127.116.11. Market size and forecast
18.104.22.168. Market size and forecast
22.214.171.124. Market size and forecast
126.96.36.199. Market size and forecast
188.8.131.52. Market size and forecast
184.108.40.206. Market size and forecast
7.1.14. Rest of Europe
220.127.116.11. Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.2. Operating business segments
8.1.3. Business performance
8.1.4. Key strategic moves and developments
8.2. DEXCOM, INC.
8.2.2. Business performance
8.2.3. Key strategic moves and developments
8.3. ECHO THERAPEUTICS, INC.
8.3.2. Business performance
8.3.3. Key strategic moves and developments
8.4. F. HOFFMANN-LA ROCHE LTD.
8.4.2. Business performance
8.4.3. Key strategic moves and developments
8.5. INSULET CORPORATION
8.5.2. Business performance
8.5.3. Key strategic moves and developments
8.6. JOHNSON & JOHNSON
8.6.2. Operating business segments
8.6.3. Business performance
8.6.4. Key strategic moves and developments
8.7. MEDTRONIC PLC
8.7.2. Operating business segments
8.7.3. Business performance
8.7.4. Key strategic moves and developments
8.8. SENSEONICS HOLDINGS, INC.
8.8.2. Key strategic moves and developments
The European CGMS market is expected to witness dynamic growth, owing to rise in per capita healthcare expenditure, increase in disposable income of individuals, and growth in prevalence rates of diabetes. In addition, CGMS has various advantages over conventional glucose monitors such as greater sensitivity, higher precision, and periodic monitoring. CGMS can be used across all age groups and various healthcare settings. Moreover, the technology is applicable in artificial/bionic pancreas; hence, several CGMS and insulin pump manufacturers focus on the development of novel and advanced CGMS. However, unfavorable reimbursement policies for CGMS hinder the market growth.
Sensors market contributed for the highest share of revenue in the CGMS market. In addition, the market is expected to witness the highest growth during the analysis period, as CGM sensors are changed frequently as compared to transmitters & receivers. As the percentage of adult population is high, this segment is estimated to generate the largest market revenue. However, owing to the growth in demand for CGM devices for children, the children population segment may grow at a higher CAGR.
Based on end-user market analysis, diagnostics/clinics contributed the highest share to the market revenue. The network of health insurers with the physicians operating at the diagnostics/clinics level is expected to drive the CGMS market in European diagnostics/clinics. However, high growth of the home healthcare segment is expected, as this segment is economic as compared to treatment from healthcare institutions. In addition, home healthcare would be the suitable solution for geriatric and children population who cannot visit the clinics for diabetes treatment.
Key findings of Europe Continuous Glucose Monitoring Systems Market:
UK is projected to grow at the highest CAGR during the forecast period.
Germany generated about one-fifth of the total market revenue in 2015, and is projected to be the maximum revenue-generating country by 2022.
Sensors segment accounted for more than three-fifths of the market revenue in 2015 and is projected to exhibit prominent growth during the forecast period.
Home healthcare and diagnostic/clinics contributed over half of the market share in 2015.
Region wise, Germany leads the market, in terms of revenue, owing to favorable guidelines about pricing and fixed reimbursement budget allocation for CGM devices. In addition, the market is estimated to exhibit significant growth in Norway, Sweden, and Denmark owing to the availability of advanced diabetes care facilities, and robust clinical guidelines and standards for diabetes management.
Renowned companies, such as Senseonics and Rubin Medical, have adopted collaboration as their key strategy to commercialize their CGMS products in Denmark and Sweden. An increasing number of diabetic patients, well-structured diabetes management regime, and proactive initiatives taken by the government have encouraged several CGMS companies to invest in Europe.
Key players profiled in this report include Abbott Laboratories, DexCom Inc., Echo Therapeutics Inc., Insulet Corporation, Johnson & Johnson, Medtronic plc, Senseonics Holding Inc., and F. Hoffmann-La Roche Ltd. Other players (not profiled in this report) operating in this market include AgaMatrix, Inc., GlySure, OrSense, and Ypsomed.